Should single agents be standard therapy for urothelial tract tumors? Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urologic Neoplasms

abstract

  • Urothelial tract tumors are chemosensitive, but long-term benefit is limited to a select few. New agents must be identified. These should be evaluated in carefully designed and executed trials with careful documentation of response. Only those combinations that consistently produce complete remissions should be considered for large-scale comparisons. The effect of stage migration, and inclusion of early-stage patients with an inherently better survival, can be minimized doing these prospective trials. Ultimately, a better understanding of the biology of these tumors may allow more accurate biologic prognostication and selection of therapy for individual patients.

publication date

  • January 1989

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 2715800

Additional Document Info

start page

  • 694

end page

  • 7

volume

  • 7

number

  • 6